OTC · Biotechnology

IntelGenx Technologies Corp. (IGXT) Stock

$0.17 +0.00% OTC: IGXT Healthcare

IntelGenx Technologies Corp. operates as a specialized drug delivery firm, concentrating on the creation and production of innovative oral thin film products for the pharmaceutical industry.

Valuation

MetricValue
Price$0.17
Market Cap$29.69M
P/E Ratio-2.99
P/B Ratio-2.42
P/S Ratio28.58
EPS (TTM)$-0.06
52-Week High$0.17
52-Week Low$0.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE126.70%
ROA-119.86%
ROCE—
Gross Margin-66.79%
Operating Margin-913.47%
Net Margin-955.44%
Debt/Equity-1.27
Current Ratio0.41

Annual Financials (USD)

Metric20192020202120222023
Revenue$1.0M$2.0M$2.0M$1.0M$1.0M
Operating Profit$-10.0M$-6.0M$-8.0M$-9.0M$-9.0M
Net Profit$-12.0M$-8.0M$-9.0M$-12.0M$-10.0M
EPS$-0.13$-0.08$-0.07$-0.07$-0.06
Op Margin-1287.1%-405.7%-520.0%-990.8%-913.5%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$11.0M$11.0M$18.0M$9.0M$8.0M
Total Liabilities$11.0M$12.0M$14.0M$13.0M$21.0M
Cash$1.0M$1.0M$4.0M$1.0M$2.0M
Borrowings$9.0M$10.0M$11.0M$11.0M$16.0M

Latest News

Net Asset Value(s) Business Wire · Jul 16, 2026 Walmart's $114 folding electric scooter saves on gas and goes up to 19 miles per hour TheStreet · Jul 16, 2026 Andersen Consulting Adds Collaborating Firm Smartbridge Business Wire · Jul 16, 2026 Gartner Announces the Gartner Enterprise Risk, Audit & Compliance Conference 2026 in Grapevine Business Wire · Jul 16, 2026 Form 8.3 Business Wire · Jul 16, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-8.0M$-6.0M$-7.0M$-10.0M$-7.0M
Investing Cash Flow$3.0M$-1.0M$-5.0M$3.0M$2.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-5.0M$0$3.0M$-3.0M$1.0M
Free Cash Flow$-9.0M$-6.0M$-7.0M$-10.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.09
EV / EBITDA-5.69
FCF Yield-22.58%
Quick Ratio0.40
Interest Coverage-5.84
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACOGFAlpha Cognition Inc. $5.73 — -38.17 $35.66M 0.00%
DMTTFSmall Pharma Inc. $0.11 -9.69% -2.20 $37.51M 0.00%
EMMLFOKYO Pharma Limited $0.01 +0.00% -6.57 $22.73M 0.00%
GENHGeneration Hemp, Inc. $0.22 +0.00% -3.88 $25.34M 0.00%
IBXNFIBEX Technologies Inc. $1.00 -6.54% 9.06 $25.27M 0.00%

About IntelGenx Technologies Corp.

IntelGenx Technologies Corp. operates as a specialized drug delivery firm, concentrating on the creation and production of innovative oral thin film products for the pharmaceutical industry. Their current portfolio features several oral film formulations: INT0008/2008, a Rizatriptan product addressing migraine headaches; INT0046/2018, intended for adult applications; INT0007/2006, developed for the treatment of erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, aimed at combating opioid addiction; INT0010/2006, designed to alleviate neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film for schizophrenia or bipolar 1 disorder; and INT0048/2020, catering to animal health. Furthermore, IntelGenx is advancing additional projects in its development pipeline, specifically INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established various agreements, including licensing, development, and supply arrangements with Tilray, Inc., alongside a development partnership with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.

IntelGenx Technologies Corp. is headquartered in CA.

IntelGenx Technologies Corp. (IGXT) stock trades at $0.17 with a market capitalization of $29.69M. The stock is valued at a price-to-earnings (P/E) ratio of -2.99, price-to-book of -2.42, price-to-sales of 28.58. Over the past 52 weeks the stock has ranged between $0.16 and $0.17, and currently trades at its 52-week high.

On profitability, IntelGenx Technologies Corp. generates a return on equity (ROE) of 126.70% — well above the market average, a sign of a high-quality business, an operating margin of -913.47%, a net profit margin of -955.44%.

Official website: www.intelgenx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides